Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep:153:103029.
doi: 10.1016/j.critrevonc.2020.103029. Epub 2020 Jun 18.

Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review

Tarek Assi  1 , Joseph Kattan  2 , Elie Rassy  3 , Hussein Nassereddine  2 , Fadi Farhat  2 , Charles Honore  4 , Axel Le Cesne  4 , Julien Adam  4 , Olivier Mir  4
Affiliations
Review

Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review

Tarek Assi et al. Crit Rev Oncol Hematol. 2020 Sep.

Abstract

Well-differentiated/dedifferentiated (WD/DD) liposarcomas, the most common form of liposarcomas, constitute up to 20 % of all soft tissue sarcomas. Several oncogenes are thought to be involved in liposarcoma pathogenesis, mainly MDM2, CDK4 and HMGA2. While MDM2 inhibitors are now tested in clinical trials, a second actionable and promising target appears to be cyclin-dependent kinase 4 (CDK4), which is amplified in up to 90 % of well differentiated or dedifferentiated (WD/DD) liposarcoma. With the paucity of available therapeutic options, the inhibition of CDK4 represent a potential therapeutic option. In this paper, we review the role of CDK4/6 inhibitors in targeting the commonly identified CDK4 amplification in WD/DD liposarcoma, with an emphasis on the published and currently ongoing trials.

Keywords: Abemaciclib; CDK4; Liposarcoma; MDM2; Palbociclib; Ribociclib; Soft tissue sarcoma.

PubMed Disclaimer